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ABSTRACT 
 
Objective – Evidence of remission without specialized treatment for BPD is accumulating. 
The authors investigated whether specialized treatments are particularly indicated for 
patients at high levels of clinical severity. They examined the impact of clinical severity on 
outcomes of a randomized controlled trial of mentalization-based treatment (MBT) 
contrasted with supportive clinical management (SCM). Method – 134 patients were 
randomly allocated to MBT or SCM. The primary outcome was the absence of crisis 
events (including suicidal and severe self-injurious behaviors and hospitalization) in the 
last 6 months. Secondary outcomes included symptom distress and social and 
interpersonal function. Severity indicators were defined as (a) severity of comorbid 
psychiatric syndromes (number of Axis I diagnoses); (b) severity of BPD (number of 
positive criteria met); (c) severity of personality disturbance (number of comorbid Axis II 
diagnoses); and (d) severity of symptom distress as indicated by SCL-90 GSI scores. 
Logistic regressions were used to predict the likelihood of recovery at 18 months. Mixed-
effects regressions were applied to examine rates of change across time on the primary 
outcome and a selective subset of secondary outcomes. Results – Of the four severity 
criteria, only one was significantly associated with superior outcomes from specialized 
treatment. Greater numbers of Axis II diagnoses predicted increasing differences in rates 
of improvement between MBT and SCM. Three or more diagnoses precluded significant 
improvement without specialist therapy. Conclusions – Patients with BPD with significant 
Axis II comorbidity do better with specialist treatment. Patients whose only PD diagnosis is 
BPD do equally well with supportive clinical management. 
  
 2 
Introduction 
 
Borderline personality disorder (BPD) is a complex mental disorder of variable severity 
characterized by difficulties with emotion regulation and impulse control, and unstable 
relationships and self-image. Randomized controlled trials (RCTs) have shown a number 
of specialist psychosocial treatments to be more effective than treatment as usual (1-5).  
 
A recent RCT (2) compared mentalization-based treatment (MBT) with manualized 
structured clinical management (SCM). MBT is a specialized therapy developed to 
address a hypothesized deficit in the capacity to represent and regulate mental states in 
patients with BPD (6). SCM is a generic intervention based on routine psychiatric practice 
with advocacy work and problem-solving sessions but matching the non-specialized 
features of MBT in terms of intensity, organization and pharmacological treatment. 
Patients in SCM improved on most measures. This finding is in line with observational 
studies that report surprisingly high rates of remission in BPD (7, 8) and with trials that 
have found well-organized psychiatric treatment to be as effective on core outcomes as a 
specialist treatment (9-11). 
 
It is suggested that clinical severity indicates a need for specialist treatment for BPD (12). 
We tested this hypothesis using the comparison of MBT and SCM, predicting that higher 
levels of severity at baseline would favor MBT over SCM. At least four indicators of 
increasing severity of BPD have been suggested (13) - level of symptom distress (14), 
number of descriptive criteria met for the disorder (15), extent of comorbidity with Axis I 
disorders (16), and degree of comorbidity with other personality disorders (PDs), 
especially in different PD clusters (17, 18). If severity moderates the benefit from 
specialized interventions then the most readily discernible parameter should be identified 
to facilitate selection. We therefore explored the value of all four indicators. 
 
 
Method 
 
The original trial was a pragmatic randomized superiority trial comparing MBT with SCM 
for BPD patients following a recent crisis episode (suicide or self-harm) (2). Each patient 
was treated for 1.5 years with measurement points at baseline, six, 12 and 18 months 
post-randomization. The primary outcome measure was a crisis episode (suicide, self-
harm, or hospitalization to prevent these). Secondary outcomes were independently rated 
Global Assessment of Functioning (GAF) scores at the beginning and end of treatments 
and self-reported psychiatric symptoms, social adjustment, and interpersonal function, 
using the Beck Depression Inventory (BDI) (19), Social Adjustment Scale Self-Report 
(SAS) (20), and the Inventory of Interpersonal Problems (IIP) (21), respectively. 
Medication use was assessed at baseline and at 6-monthly intervals until the end of 
treatment. Assessors and participants were both blind to assignment. Therapists were 
randomly assigned to treatment conditions and matched for experience and professional 
training. The study was registered with the International Randomized Controlled Trial 
Number Register (ISRCTN27660668), and approved by the Local Research Ethics 
Committee for Barnet, Enfield, and Haringey Mental Health NHS Trust.  
 
 
Sample 
 
134 patients with BPD were randomized to MBT (n=71) or SCM (n=63). Inclusion criteria 
were: (1) diagnosis of BPD, (2) suicide attempt or episode of life-threatening self-harm 
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within the past six months, (3) aged 18–65. Exclusion criteria were kept minimal 
(2).Current psychiatric in-patient treatment, temporary residence, drug and alcohol misuse, 
comorbid PD, including antisocial PD, were not exclusion criteria. Pretreatment variables 
and diagnostic data are summarized in the original report (2). There were no pretreatment 
differences between the groups other than reported rape, which was more common in the 
MBT group.  
 
Indicators of severity 
 
Severity was measured at baseline in four ways: (a) severity of comorbid psychiatric 
syndromes (number of Axis I diagnoses); (b) severity of BPD (number of positive criteria 
met); (c) severity of personality disturbance (number of comorbid Axis II diagnoses); and 
(d) severity of symptom distress (indicated by SCL-90 Global Severity Index [GSI] scores) 
(22). Other possible indicators of severity were either too difficult to assess reliably (e.g. 
frequency of self-harm, severity of suicide attempts) or too prone to contextual influences 
(e.g. lengths of hospital admissions) to be used as valid indicators of clinical severity. 
 
The distribution of the four severity indicators in this sample are shown in Figure 1. All 
severity variables, except severity of BPD, were used assuming additivity and continuity; 
severity of BPD was analyzed as a dichotomous variable using six or more positive criteria 
met as the cut-point. Unexpectedly, we found little redundancy between these indicators 
as only two of them correlated significantly: the number of Axis I and Axis II diagnoses 
(Spearman rho=0.18, p<.05), and Axis I diagnoses and BPD criteria (rho=0.21, p<.02).  
 
Sample characteristics broken down by the four severity criteria are shown in Table 1. 
Associations between demographic and clinical features and severity indicators were 
calculated using appropriate non-parametric statistics including Spearman rho correlations 
and Wilcoxon rank sum tests (not shown but available from the authors). The significance 
of the associations is indicated in Table 1. Notably, unemployment was associated with 
BPD severity, and gender with number of Axis II diagnoses. These associations were 
controlled for in all subsequent analyses.  
 
 
Statistics 
 
All analyses were carried out using Stata Statistical Software Release 12 (23). Data 
analysis was by intention to treat but primary outcome observations were available for 
95% of primary outcome variables at each observation point and around 85% of 
secondary outcome or mediator variables. Logistic regressions were used to predict the 
likelihood of recovery at 18 months and mixed-effects regressions were applied to 
examine patterns of change across time on the primary outcome and a selective subset of 
secondary outcomes. Only primary model parameters directly relevant to the study 
objectives are presented here. For the logistic regressions, these are the differences in 
recovery associated with each of the severity indicators at 18 months and the coefficient 
for the severity × group interaction (indicating whether the SCM – MBT difference varied 
with different levels of severity). In order to examine the rate of change, we used mixed-
effects regression models with participants as random effects (24). For the mixed-effect 
models looking at the pattern of change, the main effect of severity is reported, along with 
the interaction with treatment group and the linear rate of change for all severity groups 
from baseline to 18 months for both treatment groups combined. The critical coefficient for 
each severity parameter was the severity × group × time interaction, indicating differential 
rate of change for the MBT and SCM groups at different levels of the severity indicator; a 
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significant coefficient for the three-way interaction indicates that the rate of improvement or 
deterioration in the MBT group was either slower or faster than in the SCM group at a 
higher or lower level of severity. As recovery is a composite variable, we followed up 
significant effects on clinical outcome measures of self-harm, suicidality, and 
hospitalization separately. None of these were normally distributed and hospitalization and 
suicide were relatively low-frequency events. Logarithmic transformation was used for self-
harm. For suicide attempts and hospitalization we used mixed-effects Poisson regression 
to create models for count responses. Secondary outcomes were analyzed with mixed-
effects linear growth curve models for normally distributed variables. Mixed-effects models 
and general estimating equations used all available data. 
 
End-of-treatment differences and change over time were analyzed by using the LOGIT, 
XTMELOGIT, XTMEPOISSON, and XTMIXED procedures in Stata version 12 for 
Windows. The four time points were coded as -3, -2, -1, and 0 in all models where 6-
monthly data were available, thereby implying that regression coefficients involving time 
measured the linear rate of change from baseline to 18 months and that regression 
intercepts referenced group differences at the last follow-up point. A likelihood ratio test 
confirmed that a linear random intercept model best fitted the outcome measures. 
 
Effects for all outcome measures were adjusted by additionally incorporating into all fitted 
models covariates for rape because the SCM group was statistically significantly, less 
likely to have this experience, and gender where this varied with levels of severity. All 
model parameters for continuous outcome measures are presented as partial 
standardized effects, whereas those for the categorical measures are presented as 
conditional odds ratios (ORs). Plots are based on predictive margins of the Group variable 
(with 95% CIs) at linear portions of the Time variable at specified levels of the severity 
indicator (e.g. one, two, three or four comorbid diagnoses). Complete tables of all 
modeling results are available upon request. 
 
 
Results 
 
Previous reports provide information concerning treatment group differences on both 
primary and secondary outcome measures (2). Only associations with severity indicators 
are considered here. As was originally reported in both groups, the multilevel mixed-effects 
logistic regression revealed that the OR associated with recovery (no suicide attempt, self-
harm, or hospital admission) increased with time (main effect of time: OR=2.97, 95% CI: 
0.2, 5.58, t(134)=3.39, p<.001, d=0.59) but the increase was greater in the group 
randomized to MBT (time × group interaction: OR=5.37, 95% CI: 1.96, 14.69, t(134)=3.27, 
p<.001, d=0.56). The number and percentage of recovered participants in the SCM and 
MBT arms at each observation point are presented in Table 2 for participants grouped 
according to four criteria for the severity of initial presentation. Table 3 contains the 
parameters obtained from logistic and mixed-effects regression models for the four 
severity indicators tested.  
 
Only one of the four severity criteria appeared to be significantly associated with outcomes 
at the end of treatment. The presence of fewer Axis II diagnoses predicted greater 
likelihood of recovery at 18 months (OR=0.46, 95% CI: 0.25, 0.83, t(134)=-2.58, p<.01, 
d=0.45). Further, there was evidence of a significant interaction between the number of 
Axis II diagnoses and treatment group (OR=2.16 95% CI: 1.00, 4.59, t(134)=1.98, p<.05, 
d=0.34), with only about one-quarter (6/23) of patients with three or more Axis II diagnoses 
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recovered at 18 months in SCM, compared with nearly three-quarters (25/34) of the MBT 
group. Table 3 shows analyses by presence or absence of comorbid Cluster A, B or C 
diagnoses. Only the presence of Cluster C diagnoses came close to predicting recovery 
(OR=4.49, 95% CI: 0.90, 22.3, z=1.84, p<.07, d=0.32). Similarly, the presence of Cluster C 
diagnoses predicted a slower rate of change for individuals in SCM but this did not reach 
significance (see Table 3). Amongst those without Cluster C diagnoses, 20/42 (48%) 
individuals in the SCM group and 27/41 (66%) individuals in the MBT group recovered by 
18 months (χ2(1) = 2.80, p<.09). Of those with Cluster C diagnoses, only 8/21 (38%) in the 
SCM group and 25/30 (83%) in MBT group had recovered at 18 months (χ2(1)=11.07, 
p<.001). 
The number of Axis I diagnoses or GSI scores at baseline did not predict the likelihood of 
recovery overall or selectively in either of the treatment groups. The number of BPD 
criteria met also failed to correlate with recovery (rho(n=130)= -0.05, ns), and both the 
main effect and the interaction of the logistic regression were insignificant. Tables 2 and 3 
also contain information concerning the rate of increase in the number of patients who 
recovered by these criteria. Again, only the number of Axis II diagnoses yielded significant 
main or interaction effects. The main effect (β=-0.156 95% CI: -0.24, -0.08, t(134)=-3.6, 
p<.001, d=0.62) and severity × group effect (β=0.126, 95% CI: 0.01, 0.23, t(134)=2.27, 
p<.023, d=0.39) could be anticipated from the logistic regression predicting 18 months 
data. However, the significant time × Axis II severity interaction (β=-0.055, 95% CI: -0.1, -
0.02, t(134)=-2.93, p<.003, d=0.51) suggests that patients with more Axis II diagnoses 
recovered at a slower rate. Overall, 38% of those with only one diagnosis in addition to 
BPD were recovered by 12 months and 64% by 18 months; only 28% and 54% of those 
with two or more additional diagnoses were recovered at these times. Importantly, the 
prediction from the baseline number of Axis II diagnoses was significantly stronger for the 
SCM group as indicated by the significant three-way interaction (severity effect on group 
differential rate of change: β=0.048, 95% CI: 0, 0.09, t(134)=1.99, p<.05, d=0.34). To 
illustrate this interaction, Figure 2a shows the linear prediction of recovery for each of the 
treatment groups at linear portions of the Time variable at one, two, three or four comorbid 
Axis II diagnoses. While the model predicts almost identical rates of recovery for the cases 
with only BPD diagnosis, the prediction of the rate of recovery decreases with each 
additional Axis II diagnosis for the SCM group, while it remains essentially unaltered for 
the MBT group. No similar associations of severity indicators with recovery rates were 
evident for Axis I, symptom distress, or BPD severity criteria. 
 
We explored whether the additional benefit from MBT impacted on the three indicators 
contributing to the definition of recovery: hospitalization, self-harm, or suicide attempts. We 
used mixed-effects Poisson regressions to model the frequency data associated with 
hospitalization and suicide attempts. The Poisson regression for the number of suicide 
attempts yielded no significant interactions with the number of Axis II diagnoses 
(IRR=1.045, 95% CI: 0.84, 1.29, t(134)=0.4, ns, d=0.07); only the interaction between 
treatment group and time was significant (IRR=0.56, 95% CI: 0.31, 0.99, t(134)=1.96, 
p<.05, d=0.34). Similar negative results emerged in relation to number of hospitalizations. 
The only component of recovery to reflect the impact of Axis II diagnosis was self-harm. 
The Poisson regression yielded a main effect for severity (IRR=1.98, 95% CI: 1.21, 3.22, 
t(134)=2.76, p<.006, d=0.48) and interaction with time (IRR=1.27, 95% CI:0.47, 1.44, 
t(134)=3.81, p<.0001, d=0.66). A significant three-way interaction indicated that the 
reduction of self-harm over the course of treatment was substantial only for those with one 
or two Axis II diagnoses in the SCM group, whilst the moderating effect was not apparent 
in the MBT group (IRR=0.79, 95% CI:0.66, 0.93, t(134)=2.75, p<.006, d=0.48). Mixed-
effects regression using logarithms of self-harm events yielded a similar three-way 
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interaction and effect size (Figure 2b) (β=-0.11, 95% CI: -0.2, -0.03, t(134)=-2.56, p<.01, 
d=0.44). Overall, MBT was more effective than SCM for individuals with a higher number 
of Axis II diagnoses in reducing self-harm.  
 
We restricted analysis of secondary outcomes to the severity indicator that yielded 
significant interactions with the primary outcome measure. Three secondary outcomes 
were considered, namely the BDI, IIP, and SAS. Linear regression predicting end-of-
treatment effects and mixed-model random effects regressions are summarized in Table 3. 
For two of the three variables there was a three-way, time × number of Axis II diagnoses × 
group interaction, with self-rated depression scores declining and interpersonal function 
improving faster in the MBT arm for individuals with three or four diagnoses. For BDI 
scores, the contrast between SCM and MBT groups was not significant at 12 and 18 
months in patients with one or two diagnoses (β=-1.09, 95% CI: -4.2, 2.1, z=-0.68, ns; β=-
1.91, 95% CI: -5.43, 1.60, z=1.07, ns, respectively). In contrast, BDI scores were 
significantly lower for individuals with three or more diagnoses in MBT treatment by 12 
months (β=-4.42, 95% CI: -8.07, -0.78, z=-2.38, p<.017) and this difference increased by 
18 months (β=-6.94, 95% CI: -10.9, -2.88, z=-3.35, p<.001). 
 
The IIP scores were marginally significantly lower at 18 months for the MBT group even for 
individuals with only BPD diagnosis with no comorbidity (β=-0.28, 95% CI: -0.54, -.01, z=-
2.01, p<.04).The size of the difference was marked at 18 months for individuals with two or 
three Axis II diagnoses (β=-.372, 95% CI: -0.55, -0.12, z=-4.20, p<.000; β=-0.47, 95% CI: -
0.67, -0.27, z=-4.7, p<.000, respectively) and became even larger for those with four 
diagnoses (β=-0.576, 95% CI: -0.899, -0.253, z=-3.49, p<.000). There was no significant 
interaction associated with social adjustment scores, but the MBT group showed better 
function independent of the number of Axis II diagnoses.  
 
To test whether baseline correlates of the number of Axis II diagnoses (such as social 
isolation, unemployment, education level, early loss, sexual abuse, physical abuse, history 
of antisocial behavior, GAF scores) or the better medical management of the multiple PD 
diagnosis group could account for the greater benefit from MBT, we examined the 
correlation between number of PD diagnoses and these risk variables, but identified no 
significant association except gender and baseline GAF scores (rho(134)=-0.24, p<.006). 
Including GAF in addition to gender in the models did not alter any of the findings. The use 
of medication, number of different classes of medication used, or use of antidepressants, 
mood stabilizers, or benzodiazepines were also not associated with group × time 
interactions. There was some indication of a relatively more rapid reduction in 
antipsychotic use in patients with a greater number of Axis II diagnoses (OR=-1.57, 95% 
CI: -3.32, 0.178, z=-1.76, p<.08). Controlling for this effect did not change any of the 
associations reported above. 
  
 
Discussion 
 
The results suggest that increasingly severe presentation of BPD predicts greater benefit 
from MBT over SCM. However, this is only true if the definition of severity is based on 
number of Axis II diagnoses. When severity was defined as the number of comorbid Axis I 
diagnoses or positive BPD criteria, or high levels of symptom distress, no relationship to 
treatment outcome was observed. Complex or severe PD, where criteria for more than one 
PD are met, may entail a range of correlated factors such as greater likelihood of being 
unemployed and greater social and interpersonal dysfunction (25), (14), accounting for the 
relatively poorer outcomes. 
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The absence of prediction from some of our severity indicators contrast with findings from 
substantially larger, longer-term follow-along studies (26-28). Gunderson and colleagues 
(26), in a prospective longitudinal study, found that severe baseline psychopathology, 
suggested by higher levels of BPD criteria and functional disability, along with childhood 
trauma, predicted poor outcomes over two years. Other studies, mostly using 
retrospectively collected data, have identified other predictors of variations in the 
longitudinal course of the disorder, including affective disorder, substance abuse, 
dysphoria, and comorbid PDs. Only the latter influenced treatment outcomes in the 
present, smaller, sample. Perhaps these variables influence the longitudinal course of 
BPD but not treatment outcomes. 
 
Specifically, the results suggest that the addition of Cluster C disorders rather than other 
Cluster B disorders, impacts negatively on treatment outcomes. In a study on the long-
term course of global functioning in patients in therapy with mixed PD, Kvarstein and 
Karterud also found that avoidant traits were a negative prognostic factor (29). Whilst the 
risk-taking behaviors of patients with BPD represent an initial treatment challenge to 
services, the long-term functional outcomes, including social impairment, are more 
problematic (30). It is possible that the combination of BPD and avoidant features may 
increase associated social impairment (31), maintaining impairments of emotion regulation 
(32) by limiting exposure to potentially corrective social influences. 
 
Beyond understanding the prediction of treatment outcome overall, our results underscore 
the importance of multiple PD diagnoses as an indicator for MBT. We controlled for 
potentially confounding demographic and clinical correlates (gender, age, and rape), and 
yet MBT appeared particularly beneficial for patients whose BPD was embedded in other 
personality problems. How can we explain the paradox that a therapy specifically designed 
for BPD is particularly beneficial for those with additional problems beyond the target of the 
therapy? We have limited data to answer this question.. But, first, while MBT was designed 
for BPD, it may have broader scope.  Mentalizing is a key component of self-identity and a 
central aspect of interpersonal relationships. Thus, improvements in mentalizing may 
impact on a range of disordered mental processes whatever the source of pathology.  If 
PD is conceptualized as a serious impairment in interpersonal relationships, intimacy, 
identity, and self-direction (33), enhancing mentalizing might benefit PD as a whole, 
regardless of subtype. In contrast, SCM is more restricted in scope which makes it less 
relevant to patients’ functional problems. 
 
Second, assuming PDs to be more discrete diagnostic groupings, MBT may effectively 
address treatment-interfering behaviors, allowing a more generic set of processes that 
improve affect regulation to emerge. Implicit to this argument is the assumption that 
various treatment models for BPD act via a dual set of mechanisms: (a) a generic 
rehabilitative component, which restores the regulation of emotion via a generic set of 
processes embedded in the therapeutic relationship; (b) a set of modality-specific 
mechanisms, designed to maintain engagement in treatment and address aspects of the 
patients’ presentation that potentially undermine the rehabilitative component. We might 
argue that SCM contains many elements of the former but MBT training ensures that the 
generic component can be delivered despite the interpersonal challenges linked to 
multiple PD diagnoses.  
 
Third, the advantage of MBT may be due to its reduction of the potential for psychotherapy 
to do harm to patients with BPD (34). Therapists delivering SCM may have inadvertently 
caused some harm. Betan and colleagues (35) found that therapist countertransference to 
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Cluster C patients was parental/protective, with therapists wishing to protect/nurture the 
patient above and beyond normal positive feelings toward the patient. MBT specifically 
cautions therapists against overprotective/nurturing interactions because of the danger of 
overstimulation of the attachment system (36).  
 
This study tentatively suggests which patients with BPD may need a specialist treatment 
such as MBT but the observations should be considered only preliminary. The trial was not 
powered to examine moderating variables, and should be followed by either further, 
specially designed investigations or a full meta-analytic study. Although having a baseline 
indicator of suitability is helpful, differences in outcome were observed at the end of an 18-
month treatment. It would be more valuable to have indicators of the need for particular 
types of therapy during the course of treatment, in order to move towards a stepped-care 
approach.  
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